APOE Genotype
Apolipoprotein E gene variants (ε2, ε3, ε4) — the strongest common genetic risk factor for Alzheimer's disease.
Optimal Range
ε3/ε3 (neutral risk) · ε4 carriers at elevated risk
Why It Matters
Carrying one APOE4 allele increases Alzheimer's risk ~3x; two copies increase it ~12x. Knowing your APOE status enables aggressive preventive strategies including metabolic optimization, exercise, sleep, and early monitoring.
Understanding APOE Genotype
The APOE gene encodes apolipoprotein E, a protein involved in cholesterol transport, neuronal repair, and amyloid-beta clearance in the brain. Three common variants exist: ε2, ε3, and ε4. Since everyone carries two copies (one from each parent), six genotype combinations are possible. The ε3/ε3 genotype is the most common (found in ~60% of the population) and represents neutral risk.
The ε4 allele is the most clinically significant variant. Approximately 25% of the population carries at least one copy. One ε4 allele (ε3/ε4) increases Alzheimer's disease risk approximately 3-fold, while two copies (ε4/ε4, found in ~2-3% of the population) increase risk approximately 12-fold. The ε4 allele impairs amyloid-beta clearance from the brain, promotes neuroinflammation, and disrupts the blood-brain barrier. It also affects lipid metabolism, with ε4 carriers tending to have higher LDL-C and total cholesterol levels.
Knowing your APOE status is empowering because Alzheimer's risk is modifiable even in ε4 carriers. The FINGER trial and related studies have shown that multimodal lifestyle intervention (aerobic exercise, cognitive training, vascular risk management, and nutrition) can significantly reduce cognitive decline. For ε4 carriers, aggressive management of cardiovascular risk factors (LDL-C, ApoB, blood pressure), regular aerobic exercise (150+ minutes per week), sleep optimization (7–8 hours, treated sleep apnea), and metabolic health maintenance become especially important preventive strategies.
Key Research
Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families
Corder EH et al. · Science (1993)
Key finding: Landmark study establishing that APOE4 gene dose is a major risk factor for late-onset Alzheimer's disease, with homozygotes having a nearly 91% lifetime risk by age 80.
A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER)
Ngandu T et al. · Lancet (2015)
Key finding: Multimodal lifestyle intervention significantly improved cognitive function in at-risk elderly individuals, demonstrating that dementia risk is modifiable through lifestyle.